Loading patent…
AssigneeGenmab A/S
InventorsJan G. J. Van de Winkel, Marcus Antonius Van Dijk, Janine Schuurman, Arnout F. Gerritsen, Ole Baadsgaard, Jørgen Petersen
Estimating the term…
Isolated human monoclonal antibodies which specifically bind to IL-15 (e.g., human IL-15), and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced in a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
A method of treating psoriasis caused by the proinflammatory effects of human IL-15, comprising administering to a subject a monoclonal antibody or antigen binding portion thereof which binds to human IL-15, in an amount effective to treat psoriasis, wherein the heavy chain variable region of the antibody comprises the amino acid sequence set forth in SEQ ID NO:2.
A method of treating psoriasis caused by the proinflammatory effects of human IL-15, comprising administering to a subject a monoclonal antibody or antigen binding portion thereof which binds to human IL-15, in an amount effective to treat psoriasis, wherein the light chain variable region of the antibody comprises the amino acid sequence set forth in SEQ ID NO:4.
A method of treating psoriasis caused by the proinflammatory effects of human IL-15, comprising administering to a subject a monoclonal antibody or antigen binding portion thereof which binds to human IL-15, in an amount effective to treat psoriasis, wherein the heavy and light chain variable regions of the antibody comprise the amino acid sequences set forth in SEQ ID NO:2 and SEQ ID NO:4, respectively.
A method of treating psoriasis caused by the proinflammatory effects of human IL-15, comprising administering to a subject a monoclonal antibody or antigen binding portion thereof in an amount effective to treat psoriasis, wherein the antibody binds an epitope on human IL-15 recognized by an antibody comprising heavy chain and human light chain variable regions comprising the amino acid sequences set forth in SEQ ID NO:2 and SEQ ID NO:4, respectively.
Dependencies are inferred from the claim text.